Brain arteriovenous malformations have a high risk of intracranial hemorrhage, which is a substantial cause of morbidity and mortality in patients with brain arteriovenous malformations. Although a variety of genetic factors leading to hereditary brain arteriovenous malformations have been extensively investigated, their pathogenesis is still not well elucidated, especially in sporadic brain arteriovenous malformations. The authors have reviewed the updated data of not only the genetic aspects of sporadic brain arteriovenous malformations, but also the architecture of microvasculature, the roles of the angiogenic factors, and the signaling pathways. This knowledge may allow us to infer the pathogenesis of sporadic brain arteriovenous malformations and develop pre-emptive treatments for them.
WinklerEALuAYRaygorKP, et al.Defective vascular signaling & prospective therapeutic targets in brain arteriovenous malformations. Neurochem Int2019; 126: 126–138.
2.
MurphyPAKimTNHuangL, et al.Constitutively active Notch4 receptor elicits brain arteriovenous malformations through enlargement of capillary-like vessels. Proc Natl Acad Sci2014; 111: 18007–18012.
3.
WalkerEJSuHShenF, et al.Arteriovenous malformation in the adult mouse brain resembling the human disease. Ann Neurol2011; 69: 954–962.
4.
WalcottBPSmithERScottRM, et al.Pial arteriovenous fistulae in pediatric patients: associated syndromes and treatment outcome. J Neurointerv Surg2013; 5: 10–14.
5.
EerolaIBoonLMMullikenJB, et al.Capillary malformation – arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet2003; 73: 1240–1249.
6.
YilmazBToktasZOAkakinA, et al.Familial occurrence of brain arteriovenous malformation: a novel ACVRL1 mutation detected by whole exome sequencing. J Neurosurg2017; 126: 1879–1883.
7.
RothbartDAwadIALeeJ, et al.Expression of angiogenic factors and structural proteins in central nervous system vascular malformations. Neurosurgery1996; 38: 915–925.
8.
HashimotoTWenGLawtonMT, et al.Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke2003; 34: 925–930.
9.
CoutoJAHuangAYKonczykDJ, et al.Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am J Hum Genet2017; 100: 546–554.
10.
NikolaevSIVetiskaSBonillaX, et al.Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med2018; 378: 250–261.
11.
Rangel-CastillaLRussinJJMartinez-del-CampoE, et al.Molecular and cellular biology of cerebral arteriovenous malformations: a review of current concepts and future trends in treatment. Neurosurg Focus2014; 37: E1.
12.
FrösenJJoutelA. Smooth muscle cells of intracranial vessels: from development to disease. Cardiovas Res2018; 114: 501–512.
13.
WinklerEABirkHBurkhardtJ-K, et al.Reductions in brain pericytes are associated with arteriovenous malformation vascular instability. J Neurosurg2018; 129: 1464–1474.
14.
ChenWGuoYWalkerEJ, et al.Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain. Arterioscler Thromb Vasc Biol2013; 33: 305–310.
15.
ChenYZhuWBollenAW, et al.Evidence of inflammatory cell involvement in brain arteriovenous malformations. Neurosurgery2008; 62: 1340–1350.
16.
BhogalPLansleyJWongK, et al.Vessel wall enhancement of a ruptured intra-nidal aneurysm in a brain arteriovenous malformation. Interv Neuroradiol2019; 25: 310–314.
17.
GuoYSaundersTSuH, et al.Silent intralesional microhemorrhage as a risk factor for brain arteriovenous malformation rupture. Stroke2012; 43: 1240–1246.
18.
AblaAANelsonJKimH, et al.Silent arteriovenous malformation hemorrhage and the recognition of ‘unruptured’ arteriovenous malformation patients who benefit from surgical intervention. Neurosurgery2015; 76: 592–600.
19.
LeblancGGGolanovEAwadIA, et al.Biology of vascular malformations of the brain. Stroke2009; 40: 694–702.
20.
VorbrodtAWDobrogowskaDHTarnawskiM. Immunogold study of interendothelial junction-associated and glucose transporter proteins during postnatal maturation of the mouse blood-brain barrier. J Neurocytol2001; 30: 705–716.
21.
EtcheversHCVincentCLe DouarinNM, et al.The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. Development2001; 128: 1059–1068.
22.
McCormickWF. The pathology of vascular (“arteriovenous”) malformations. J Neurosurg1966; 24: 807–816.
23.
GladingAHanJStocktonRA, et al.KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell-cell junctions. J Cell Biol2007; 179: 247–254.
24.
ClatterbuckREEberhartCGCrainBJ, et al.Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry2001; 71: 188–192.
25.
ThomasJMSurendranSAbrahamM, et al.Gene expression analysis of nidus of cerebral arteriovenous malformations reveals vascular structures with deficient differentiation and maturation. PLoS One2018; 13: e0198617.
26.
KoizumiTShiraishiTHagiharaN, et al.Expression of vascular endothelial growth factors and their receptors in and around intracranial arteriovenous malformations. Neurosurgery2002; 50: 117–124.
27.
HashimotoTWuYLawtonMT, et al.Coexpression of angiogenic factors in brain arteriovenous malformations. Neurosurgery2005; 56: 1058–1065.
28.
FerreiraRAmarAChenTC, et al.MicroRNA-18a improves human cerebral arteriovenous malformation endothelial cell function. Stroke2014; 45: 293–297.
29.
JabbourMNElderJBSamuelsonCG, et al.Aberrant angiogenic characteristics of human brain arteriovenous malformation endothelial cells. Neurosurgery2009; 64: 139–148.
30.
KomiyamaM. Pathogenesis of brain arteriovenous malformations. Neurol Med Chir (Tokyo)2016; 56: 317–325.
31.
NielsenCMHuangLMurphyPA, et al.Mouse models of cerebral arteriovenous malformation. Stroke2016; 47: 293–300.
32.
ChenWSunZHanZ, et al.De novo cerebrovascular malformation in the adult mouse after endothelial Alk1 deletion and angiogenic stimulation. Stroke2014; 45: 900–902.
33.
SuHTihanTYoungW, et al.Distinctive distribution of lymphocytes in unruptured and previously untreated brain arteriovenous malformation. Neuroimmunol Neuroinflamm2014; 1: 147–152.
34.
HuangJSongJQuM, et al.MicroRNA-137 and microRNA-195* inhibit vasculogenesis in brain arteriovenous malformations. Ann Neurol2017; 82: 371–384.
35.
ZhuWChenWZouD, et al.Thalidomide reduces hemorrhage of brain arteriovenous malformations in a mouse model. Stroke2018; 49: 1232–1240.
36.
HuoRFuWLiH, et al.RNA sequencing reveals the activation of Wnt signaling in low flow rate brain arteriovenous malformations. J Am Heart Assoc2019; 8: e012746.
37.
PayneLBZhaoHJamesCC, et al.The pericyte microenvironment during vascular development. Microcirculation2019; 26: e12554.
38.
KislerKNelsonARRegeSV, et al.Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nat Neurosci2017; 20: 406–416.
39.
SweeneyMDAyyaduraiSZlokovicBV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci2016; 19: 771–783.
40.
HashimotoTLamTBoudreauNJ, et al.Abnormal balance in the angiopoietin-tie2 system in human brain arteriovenous malformations. Circ Res2001; 89: 111–113.
41.
DardenJPayneLBZhaoH, et al.Excess vascular endothelial growth factor-A disrupts pericyte recruitment during blood vessel formation. Angiogenesis2019; 22: 167–183.
42.
YildirimOBicerAOzkanA, et al.Expression of platelet-derived growth factor ligand and receptor in cerebral arteriovenous and cavernous malformations. J Clin Neurosci2010; 17: 1557–1562.
43.
YoungWLYangGY. Are there genetic influences on sporadic brain arteriovenous malformations?Stroke2004; 35: 2740–2745.
44.
SandalciogluIEAsgariSWendeD, et al.Proliferation activity is significantly elevated in partially embolized cerebral arteriovenous malformations. Cerebrovasc Dis2010; 30: 396–401.
45.
WalkerEJSuHShenF, et al.Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain. Stroke2012; 43: 1925–1930.
46.
HashimotoTLawtonMTWenG, et al.Gene microarray analysis of human brain arteriovenous malformations. Neurosurgery2004; 54: 410–425.
47.
KimGHHahnDKKellnerCP, et al.Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations. Stroke2008; 39: 2274–2279.
48.
WuCYWangYHMengFG, et al.Development of stereotactic neurosurgery in China. Neurosurgery2005; 56: 851–860.
ChengPMaLShaligramS, et al.Effect of elevation of vascular endothelial growth factor level on exacerbation of hemorrhage in mouse brain arteriovenous malformation. J Neurosurg2019; 1: 1–8.
52.
DaltonADobsonGPrasadM, et al.De novo intracerebral arteriovenous malformations and a review of the theories of their formation. Br J Neurosurg2018; 32: 305–311.
53.
CataltepeSArikanMCLiangX, et al.Fatty acid binding protein 4 expression in cerebral vascular malformations: implications for vascular remodelling. Neuropathol Appl Neurobiol2015; 41: 646–656.
54.
CunhaSIMagnussonPUDejanaE, et al.Deregulated TGF-β/BMP signaling in vascular malformations. Circ Res2017; 121: 981–999.
55.
PawlikowskaLTranMNAchrolAS, et al.Polymorphisms in transforming growth factor-β-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke2005; 36: 2278–2280.
56.
SimonMFrankeDLudwigM, et al.Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system. J Neurosurg2006; 104: 945–949.
57.
WalcottBP. BMP signaling modulation attenuates cerebral arteriovenous malformation formation in a vertebrate model. J Cereb Blood Flow Metab2014; 34: 1688–1694.
58.
JanesMRZhangJLiL-S, et al.Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell2018; 172: 578–589.e17.
59.
YaoJGuihardPJBlazquez-MedelaAM, et al.Matrix Gla protein regulates differentiation of endothelial cells derived from mouse embryonic stem cells. Angiogenesis2016; 19: 1–7.
60.
WalcottBPWinklerEAZhouS, et al.Identification of a rare BMP pathway mutation in a non-syndromic human brain arteriovenous malformation via exome sequencing. Hum Genome Var2018; 5: 18001.
61.
Hill-FelbergSWuHHTomsSA, et al.Notch receptor expression in human brain arteriovenous malformations. J Cell Mol Med2015; 19: 1986–1993.
62.
MurphyPAKimTNLuG, et al.Notch4 normalization reduces blood vessel size in arteriovenous malformations. Sci Transl Med2012; 4: 117ra8.
63.
BeneditoRTrindadeAHirashimaM, et al.Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev Biol2008; 8: 117.
64.
SainsonRCAAotoJNakatsuMN, et al.Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J2005; 19: 1027–1029.
65.
KrebsLTShutterJRTanigakiK, et al.Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev2004; 18: 2469–2473.
66.
LawsonNDScheerNPhamVN, et al.Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development2001; 128: 3675–3683.
67.
VillaNWalkerLLindsellCE, et al.Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev2001; 108: 161–164.
68.
MurphyPALuGShiahS, et al.Endothelial Notch signaling is upregulated in human brain arteriovenous malformations and a mouse model of the disease. Lab Invest2009; 89: 971–982.
69.
CarlsonTRYanYWuX, et al.Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous. PNAS2005; 102: 9884–9889.
70.
MouchtourisNJabbourPMStarkeRM, et al.Biology of cerebral arteriovenous malformations with a focus on inflammation. J Cereb Blood Flow Metab2015; 35: 167–175.
71.
ZhuGeQZhongMZhengW, et al.Notch-1 signalling is activated in brain arteriovenous malformations in humans. Brain2009; 132: 3231–3241.
72.
LiSWangRWangY, et al.Receptors of the Notch signaling pathway are associated with hemorrhage of brain arteriovenous malformations. Mol Med Rep2014; 9: 2233–2238.
73.
MurphyPALamMTYWuX, et al.Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. Proc Natl Acad Sci2008; 105: 10901–10906.
74.
DelevDPavlovaAGroteA, et al.NOTCH4 gene polymorphisms as potential risk factors for brain arteriovenous malformation development and hemorrhagic presentation. J Neurosurg2016; 126: 1552–1559.
75.
HermantoYTakagiYIshiiA, et al.Immunohistochemical analysis of Sox17 associated pathway in brain arteriovenous malformations. World Neurosurg2016; 87: 573–583.e2.
76.
CoradaMOrsenigoFMoriniMF, et al.Sox17 is indispensable for acquisition and maintenance of arterial identity. Nat Commun2013; 4: 1–14.
77.
NorrisJSValianteTAWallaceMC, et al.A simple relationship between radiological arteriovenous malformation hemodynamics and clinical presentation: a prospective, blinded analysis of 31 cases. J Neurosurg2009; 90: 673–679.
78.
OkaMKushamaeMAokiT, et al.KRAS G12D or G12V mutation in human brain arteriovenous malformations. World Neurosurg2019; 126: e1365–e1373.
79.
Al-OlabiLPolubothuSDowsettK, et al.Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest2018; 128: 1496–1508.
80.
PriemerDSVortmeyerAOZhangS, et al.Activating KRAS mutations in arteriovenous malformations of the brain: frequency and clinicopathologic correlation. Hum Pathol2019; 89: 33–39.
81.
SimanshuDKNissleyDVMcCormickF. RAS proteins and their regulators in human disease. Cell2017; 170: 17–33.
82.
PapkeBDerCJ. Drugging RAS: know the enemy. Science2017; 355: 1158–1163.
83.
SaeedOLopez-BeltranAFisherKW, et al.RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J Clin Pathol2019; 72: 135–139.
84.
HongTYanYLiJ, et al.High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain2019; 142: 23–34.
85.
KarpathiouGChauleurCDa CruzV, et al.Vascular lesions of the female genital tract: clinicopathologic findings and application of the ISSVA classification. Pathophysiology2017; 24: 161–167.
86.
LimayeNKangasJMendolaA, et al.Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet2015; 97: 914–921.
87.
CoutoJAViveroMPKozakewichHPW, et al.A somatic MAP3K3 mutation is associated with verrucous venous malformation. Am J Hum Genet2015; 96: 480–486.
88.
Zúñiga-CastilloMTengCLTengJMC. Genetics of vascular malformation and therapeutic implications. Curr Opin Pediatr2019; 31: 498–508.
89.
SaliouGEyriesMIacobucciM, et al.Clinical and genetic findings in children with central nervous system arteriovenous fistulas. Ann Neurol2017; 82: 972–980.
90.
QueisserABoonLMVikkulaM. Etiology and genetics of congenital vascular lesions. Otolaryngol Clin North Am2018; 51: 41–53.
91.
YuJStreicherJLMedneL, et al.EPHB4 mutation implicated in capillary malformation – arteriovenous malformation syndrome: a case report. Pediatr Dermatol2017; 34: e227–e230.
92.
OlaRDubracAHanJ, et al.PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun2016; 7: 13650.
93.
OlaRKünzelSHZhangF, et al.SMAD4 prevents flow induced arteriovenous malformations by inhibiting casein kinase 2. Circulation2018; 138: 2379–2394.
94.
JinYMuhlLBurmakinM, et al.Endoglin prevents vascular malformation by regulating flow-induced cell migration and specification through VEGFR2 signalling. Nat Cell Biol2017; 19: 639–652.
95.
MotekiYAkagawaHNiimiY, et al.Novel RASA1 mutations in Japanese pedigrees with capillary malformation-arteriovenous malformation. Brain Dev2019; 41: 812–816.
96.
LebrinFSrunSRaymondK, et al.Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med2010; 16: 420–428.
97.
DavisRBPahlKDattoNC, et al.Notch signaling pathway is a potential therapeutic target for extracranial vascular malformations. Sci Rep2018; 8: 1–10.
98.
HanCChoeSKimYH, et al.VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis2014; 17: 823–830.
99.
GilbertMRDignamJJArmstrongTS, et al.A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med2014; 370: 699–708.
100.
StarkeRMMcCarthyDKomotarRJ, et al.Somatic KRAS mutation found in sporadic arteriovenous malformations. Clin Neurosurg2018; 83: E14–E15.
101.
KangasJNätynkiMEklundL. Development of molecular therapies for venous malformations. Basic Clin Pharmacol Toxicol2018; 123: 6–19.
102.
LekwuttikarnRLimYHAdmaniS, et al.Genotype-guided medical treatment of an arteriovenous malformation in a child. JAMA Dermatol2019; 155: 256–257.
103.
LongGVStroyakovskiyDGogasH, et al.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med2014; 371: 1877–1888.
104.
RutkowskiPLugowskaIKosela-PaterczykH, et al.Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther2015; 8: 2251–2259.
105.
GreeneAKGossJA. Vascular anomalies: from a clinicohistologic to a genetic framework. Plast Reconstr Surg2018; 141: 709e–717e.
106.
PhungTLZivKDabydeenD, et al.Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell2006; 10: 159–170.
107.
ChelliahMPDoHMZinnZ, et al.Management of complex arteriovenous malformations using a novel combination therapeutic algorithm. JAMA Dermatol2018; 154: 1316–1319.
108.
AdamsDMTrenorCCIIIHammillAM, et al.Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies2016; 137: e20153257.
